Toulouse, France – A 51-year-old former pianist is pursuing legal action against the Toulouse University Hospital (CHU) seeking over €4 million in damages, alleging that a prescribed medication led to a severe and debilitating loss of vision. Laurence Berdot-Talmier claims errors in the prescription and monitoring of the drug plaquenil resulted in a vision deficit of 84%, fundamentally altering her life.
Berdot-Talmier, a Toulousaine who previously enjoyed a career as a pianist, now experiences near-total blindness. She attributes her condition to medical errors during treatment for a severe case of Raynaud’s syndrome, a condition affecting blood circulation in the extremities. Her case highlights the potential for serious side effects from commonly prescribed medications and the importance of careful patient monitoring.
The legal proceedings, initiated in March 2026, involve two separate claims: one before the Toulouse administrative court and another against an ophthalmologist in the city, according to her lawyer, Me Pascal Nakache. The requested €4 million is intended to cover lost professional income, future assistance needs, and the significant emotional distress caused by the vision loss.
The Course of Treatment and Subsequent Vision Loss
Berdot-Talmier began treatment with plaquenil in the early 2000s, prescribed by doctors at Purpan Hospital for her Raynaud’s syndrome. She recalls being advised to consult an ophthalmologist to rule out any contraindications, a step that was taken, but initially revealed no concerns. However, beginning in 2006, she began experiencing a decline in her visual acuity, which she reported to her medical team. It wasn’t until 2007 that her ophthalmologist recommended discontinuing the plaquenil, by which point she had developed a central scotoma – a blind spot in the center of her vision – and her eyesight continued to deteriorate.
Despite stopping the medication, Berdot-Talmier’s vision continued to worsen. She successfully pursued a career change, earning a doctorate in psychology in 2017. However, by 2019-2020, her vision had deteriorated to the point where she was unable to continue working, losing interim positions at a university and a hospital due to her disability. She now relies on a guide dog for mobility.
Expert Opinion Challenges Treatment Protocol
A key element of Berdot-Talmier’s case rests on an expert medical report commissioned by the Toulouse administrative court in July 2021 and completed in September 2025. The report, conducted by an ophthalmologist from Montpellier, reportedly questions the initial decision to prescribe plaquenil for Raynaud’s syndrome, suggesting it wasn’t necessarily the most appropriate treatment. The expert criticized the lack of sufficient reevaluation of her dosage between 2003 and 2007, particularly after she experienced significant weight loss – over 15 kilograms – which could have altered the drug’s impact.
According to Me Nakache, the expert’s report also highlighted a lack of coordination of care within the internal medicine department at Purpan Hospital. “The expert points out that the initiation of plaquenil as a first-line treatment was questionable and not necessarily needed to treat Raynaud’s syndrome,” Nakache stated. “There was insufficient reevaluation of the patient between 2003 and 2007.”
Hospital Response and Ongoing Legal Battle
While multiple experts have reportedly identified medical errors in Berdot-Talmier’s case, the CHU de Toulouse has not publicly acknowledged fault and is contesting the findings. The hospital declined to comment on the ongoing legal proceedings when contacted. Berdot-Talmier expressed her frustration with the hospital’s stance, stating she simply wants acknowledgement of the errors and fair compensation for the profound impact the vision loss has had on her life.
“It’s a monstrous fault on the part of the doctor with terrible consequences for this patient’s life and a disregard on the part of the hospital that offers nothing,” Nakache added. The court is expected to reach a judgment in the next three to four years.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
The outcome of this case could have broader implications for patient safety and the monitoring of medications with known potential side effects. As the legal process unfolds, it will be crucial to follow developments and understand the implications for medical practice and patient care.
What are your thoughts on this case? Share your comments below and let us grasp what you consider.
